Proteasomal down-regulation of the proapoptotic MST2 pathway contributes to BRAF inhibitor resistance in melanoma

The loss of MST2 pathway protein expression in BRAF inhibitor resistant melanoma cells is due to ubiquitination and subsequent proteasomal degradation and prevents MST2-mediated apoptosis. The RAS-RAF-MEK-ERK pathway is hyperactivated in most malignant melanomas, and mutations in BRAF or NRAS account for most of these cases. BRAF inhibitors (BRAFi) are highly efficient for treating patients with BRAFV600E mutations, but tumours frequently acquire resistance within a few months. Multiple resistance mechanisms have been identified, due to mutations or network adaptations that revive ERK signalling. We have previously shown that RAF proteins inhibit the MST2 proapoptotic pathway in a kinase-independent fashion. Here, we have investigated the role of the MST2 pathway in mediating resistance to BRAFi. We show that the BRAFV600E mutant protein, but not the wild-type BRAF protein, binds to MST2 inhibiting its proapoptotic signalling. Down-regulation of MST2 reduces BRAFi-induced apoptosis. In BRAFi-resistant cell lines, MST2 pathway proteins are down-regulated by ubiquitination and subsequent proteasomal degradation rendering cells refractory to MST2 pathway–induced apoptosis. Restoration of apoptosis can be achieved by increasing MST2 pathway protein expression using proteasome inhibitors. In summary, we show that the MST2 pathway plays a role in the acquisition of BRAFi resistance in melanoma.

[1]  Z. Jie,et al.  RNF6 promotes the migration and invasion of breast cancer by promoting the ubiquitination and degradation of MST1 , 2021, Experimental and therapeutic medicine.

[2]  Jing Sun,et al.  lncRNA TINCR attenuates the proliferation and invasion, and enhances the apoptosis of cutaneous malignant melanoma cells by regulating the miR-424-5p/LATS1 axis , 2021, Oncology reports.

[3]  N. Miller,et al.  A Review of Epidemiology and Cancer Biology of Malignant Melanoma , 2021, Cureus.

[4]  Lucía García-Gutiérrez,et al.  Resistance to Targeted Therapy and RASSF1A Loss in Melanoma: What Are We Missing? , 2021, International journal of molecular sciences.

[5]  W. Kolch,et al.  Hidden Targets in RAF Signalling Pathways to Block Oncogenic RAS Signalling , 2021, Genes.

[6]  D. Matallanas,et al.  IQGAP1 Is a Scaffold of the Core Proteins of the Hippo Pathway and Negatively Regulates the Pro-Apoptotic Signal Mediated by This Pathway , 2021, Cells.

[7]  C. Kiel,et al.  The Ins and Outs of RAS Effector Complexes , 2021, Biomolecules.

[8]  S. Cook,et al.  Inhibition of RAF dimers: it takes two to tango , 2020, Biochemical Society transactions.

[9]  D. Schadendorf,et al.  Integrated molecular drivers coordinate biological and clinical states in melanoma , 2020, Nature Genetics.

[10]  I. Proietti,et al.  Mechanisms of Acquired BRAF Inhibitor Resistance in Melanoma: A Systematic Review , 2020, Cancers.

[11]  W. Kolch,et al.  Characterisation of HRas local signal transduction networks using engineered site-specific exchange factors , 2020, Small GTPases.

[12]  P. Rutkowski,et al.  Targeted Therapy in Melanoma and Mechanisms of Resistance , 2020, International journal of molecular sciences.

[13]  B. Thompson YAP/TAZ: Drivers of Tumor Growth, Metastasis, and Resistance to Therapy , 2020, BioEssays : news and reviews in molecular, cellular and developmental biology.

[14]  W. Kolch,et al.  Targeting MAPK Signaling in Cancer: Mechanisms of Drug Resistance and Sensitivity , 2020, International journal of molecular sciences.

[15]  Sameh K. Mohamed,et al.  Accurate prediction of kinase-substrate networks using knowledge graphs , 2019, bioRxiv.

[16]  P. Marchetti,et al.  Drug resistance of BRAF-mutant melanoma: Review of up-to-date mechanisms of action and promising targeted agents. , 2019, European journal of pharmacology.

[17]  Nikki M. Carroll,et al.  Melanoma incidence, recurrence, and mortality in an integrated healthcare system: A retrospective cohort study , 2019, Cancer medicine.

[18]  C. Wellbrock,et al.  Phenotype plasticity as enabler of melanoma progression and therapy resistance , 2019, Nature Reviews Cancer.

[19]  K. Hofmann,et al.  Activity-based E3 ligase profiling uncovers an E3 ligase with esterification activity , 2018, Nature.

[20]  Ton Wang,et al.  BRAF and MEK Inhibitors: Use and Resistance in BRAF-Mutated Cancers , 2018, Drugs.

[21]  C. Wellbrock,et al.  Overcoming resistance to BRAF inhibitors. , 2017, Annals of translational medicine.

[22]  Daniela Pankova,et al.  TGF-β Targets the Hippo Pathway Scaffold RASSF1A to Facilitate YAP/SMAD2 Nuclear Translocation. , 2016, Molecular cell.

[23]  D. Matallanas,et al.  The MST/Hippo Pathway and Cell Death: A Non-Canonical Affair , 2016, Genes.

[24]  Walter Kolch,et al.  Phosphorylation of RAF Kinase Dimers Drives Conformational Changes that Facilitate Transactivation , 2015, Angewandte Chemie.

[25]  C. Berking,et al.  Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms. , 2015, European journal of cancer.

[26]  Jeffrey E. Lee,et al.  Genetic variants in Hippo pathway genes YAP1, TEAD1 and TEAD4 are associated with melanoma‐specific survival , 2015, International journal of cancer.

[27]  Nan Wang,et al.  A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells* , 2015, Molecular & Cellular Proteomics.

[28]  A. Rust,et al.  BRAF inhibitor resistance mediated by the AKT pathway in an oncogenic BRAF mouse melanoma model , 2015, Proceedings of the National Academy of Sciences.

[29]  G. von Heijne,et al.  Tissue-based map of the human proteome , 2015, Science.

[30]  K. Flaherty,et al.  One Hippo and many masters: differential regulation of the Hippo pathway in cancer. , 2014, Biochemical Society transactions.

[31]  Boris N. Kholodenko,et al.  Protein interaction switches coordinate Raf-1 and MST2/Hippo signalling , 2014, Nature Cell Biology.

[32]  M. Skobe,et al.  Anti-apoptotic BCL-2 proteins govern cellular outcome following B-RAFV600E inhibition and can be targeted to reduce resistance , 2014, Oncogene.

[33]  David J. Duffy,et al.  GSK3 Inhibitors Regulate MYCN mRNA Levels and Reduce Neuroblastoma Cell Viability through Multiple Mechanisms, Including p53 and Wnt Signaling , 2013, Molecular Cancer Therapeutics.

[34]  D. Zecchin,et al.  BRAF V600E Is a Determinant of Sensitivity to Proteasome Inhibitors , 2013, Molecular Cancer Therapeutics.

[35]  R. Sullivan,et al.  BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma , 2013, Clinical Cancer Research.

[36]  K. Flaherty,et al.  Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. , 2012, The New England journal of medicine.

[37]  G. Prelich Gene Overexpression: Uses, Mechanisms, and Interpretation , 2012, Genetics.

[38]  M. Barbacid,et al.  Mutant K-Ras activation of the proapoptotic MST2 pathway is antagonized by wild-type K-Ras. , 2011, Molecular cell.

[39]  W. Kolch,et al.  The secret life of kinases: functions beyond catalysis , 2011, Cell Communication and Signaling.

[40]  M. Yi,et al.  RASSF1A suppresses melanoma development by modulating apoptosis and cell‐cycle progression , 2011, Journal of cellular physiology.

[41]  Y. She,et al.  Itch E3 ubiquitin ligase regulates large tumor suppressor 1 stability , 2011, Proceedings of the National Academy of Sciences.

[42]  W. Kolch,et al.  Raf family kinases: old dogs have learned new tricks. , 2011, Genes & cancer.

[43]  R. Aqeilan,et al.  Negative regulation of the Hippo pathway by E3 ubiquitin ligase ITCH is sufficient to promote tumorigenicity. , 2011, Cancer research.

[44]  D. Lim,et al.  Cross-Regulation between Oncogenic BRAFV600E Kinase and the MST1 Pathway in Papillary Thyroid Carcinoma , 2011, PloS one.

[45]  Muffy Calder,et al.  The Mammalian MAPK/ERK Pathway Exhibits Properties of a Negative Feedback Amplifier , 2010, Science Signaling.

[46]  D. Rigel,et al.  Epidemiology of melanoma. , 2010, Seminars in cutaneous medicine and surgery.

[47]  D. Pan,et al.  The hippo signaling pathway in development and cancer. , 2010, Developmental cell.

[48]  Kam Y. J. Zhang,et al.  Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma , 2010, Nature.

[49]  Chao Zhang,et al.  RAF inhibitors transactivate RAF dimers and ERK signaling in cells with wild-type BRAF , 2010, Nature.

[50]  G. Pfeifer,et al.  The RASSF proteins in cancer; from epigenetic silencing to functional characterization. , 2009, Biochimica et biophysica acta.

[51]  Walter Kolch,et al.  RASSF1A elicits apoptosis through an MST2 pathway directing proapoptotic transcription by the p73 tumor suppressor protein. , 2007, Molecular cell.

[52]  J. Fridlyand,et al.  Distinct sets of genetic alterations in melanoma. , 2005, The New England journal of medicine.

[53]  M. Baccarini Second nature: Biological functions of the Raf‐1 “kinase” , 2005, FEBS letters.

[54]  Walter Kolch,et al.  Role of the Kinase MST2 in Suppression of Apoptosis by the Proto-Oncogene Product Raf-1 , 2004, Science.

[55]  G. Reifenberger,et al.  Frequent alterations of Ras signaling pathway genes in sporadic malignant melanomas , 2004, International journal of cancer.

[56]  Jing Chen,et al.  Raf-1 promotes cell survival by antagonizing apoptosis signal-regulating kinase 1 through a MEK–ERK independent mechanism , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[57]  A. Ciechanover,et al.  Modes of regulation of ubiquitin‐mediated protein degradation , 2000, Journal of cellular physiology.

[58]  E. Yeh,et al.  Characterization of NEDD8, a Developmentally Down-regulated Ubiquitin-like Protein* , 1997, The Journal of Biological Chemistry.

[59]  Andrew B. Sholl,et al.  Bortezomib sensitizes thyroid cancer to BRAF inhibitor in vitro and in vivo. , 2018, Endocrine-related cancer.